Almost all CCM cases are positive for Vimentin, while PgR and EMA are positive in 87.5% and 83.3% of cases, respectively.[11] It is not advisable to shorten the follow-up period for patients with a low Ki-67 index, as recurrence has been observed even in these cases. This evidence concerns the gene MUC1 and cerebral cavernous malformation.